Bioceres faces mid-term headwinds as it navigates a $4 million inventory write-down and complex debt disputes, while shifting focus to high-margin fertilizers and Brazilian market expansion.
Fiscal 2026 revenue declined 18% due to litigation and business disruptions, with a $4M inventory adjustment, though cost cuts and portfolio rationalization aim to improve margins.
Bioceres Crop Solutions reported an 18% revenue decline for fiscal 2026, hampered by ongoing litigation and a strategic exit from its legacy seed business. Management is now pivoting toward a leaner operating model, targeting a 40% gross margin by 2027 through portfolio rationalization and significant SG&A cost reductions.
The decline was primarily driven by international business disruptions, ongoing litigation with creditors, and the strategic decision to wind down the legacy seed business model.
The company is implementing a portfolio rationalization strategy, cutting SG&A expenses, and focusing on high-margin products like microbeaded fertilizers to reach a 40% gross margin by 2027.